Our main priority at Adaptimmune is to improve the outcomes of patients who are suffering from cancer via immunotherapy.
Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.
We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.
Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares